This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Todd Longsworth Biography and Net Worth

General Counsel of NovoCure

Todd Longsworth joined Novocure in 2012 and serves as General Counsel. Mr. Longsworth worked for Cephalon, Inc., a U.S. biopharmaceutical company, from 2005 to 2012, last serving as Mergers and Acquisitions, Securities and Corporate Governance Counsel. Prior to joining Cephalon, he was an associate at WilmerHale LLP, a global law firm from 2001 to 2005. Mr. Longsworth earned his B.A. from Duke University and his J.D. from the University of Pennsylvania.

What is Todd Christopher Longsworth's net worth?: The estimated net worth of Todd Christopher Longsworth is at least $3.69 million as of January 15th, 2021. Mr. Longsworth owns 123,474 shares of NovoCure stock worth more than $3,685,699 as of December 3rd. This net worth approximation does not reflect any other investments that Mr. Longsworth may own. Learn More about Todd Christopher Longsworth's net worth.
How do I contact Todd Christopher Longsworth?: The corporate mailing address for Mr. Longsworth and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Todd Christopher Longsworth's contact information.
Has Todd Christopher Longsworth been buying or selling shares of NovoCure?: Todd Christopher Longsworth has not been actively trading shares of NovoCure over the course of the past ninety days. Most recently, Todd Christopher Longsworth sold 2,339 shares of the business's stock in a transaction on Tuesday, March 8th. The shares were sold at an average price of $70.10, for a transaction totalling $163,963.90. Learn More on Todd Christopher Longsworth's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 10 times. They sold a total of 11,141 shares worth more than $188,910.17. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

Todd Christopher Longsworth Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/8/2022	Sell	2,339	$70.10	$163,963.90
3/3/2022	Sell	1,094	$74.50	$81,503.00
1/15/2021	Sell	63,814	$172.48	$11,006,638.72	123,474
2/25/2020	Sell	8,482	$81.16	$688,399.12	75,601
9/3/2019	Sell	158,440	$87.87	$13,922,122.80	113,420
2/28/2019	Sell	2,368	$53.68	$127,114.24	39,203
1/25/2019	Sell	26,874	$49.03	$1,317,632.22	36,305
1/16/2019	Sell	15,000	$45.15	$677,250.00	36,305
1/9/2019	Sell	15,000	$40.15	$602,250.00	36,305
2/23/2018	Sell	6,591	$19.83	$130,699.53	26,665
1/29/2018	Sell	11,630	$24.00	$279,120.00	16,628

Todd Christopher Longsworth Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $29.85

$25.00

$31.57

50 Day Range

MA: $16.91

$14.54

$29.85

2 Week Range

Now: $29.85

$11.66

$31.57

Volume

12,214,762 shs

Average Volume

810,497 shs

Market Capitalization

$3.23 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Missed Nvidia? Buy Elon Musk’s “Silent Partner”

From Brownstone Research | Ad

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.